Biotech | February 01, 2022
Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
The company has been manufacturing masks since the Covid-19 outbreak in 2020
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
The country is sixth among the most affected countries by active cases
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
Subscribe To Our Newsletter & Stay Updated
